Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Randomized, Observer-blind, Active-Control Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-based Influenza and SARS-CoV-2 Multi-component Vaccines in Healthy Adults

NCT05827926 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT05827926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05827926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Randomized, Observer-blind, Active-Control Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-based Influenza and SARS-CoV-2 Multi-component Vaccines in Healthy Adults
Lead sponsor
ModernaTX, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
April 14, 2023
Completion date
December 3, 2024
Enrollment
1,758 (actual)
Sites
69

Conditions

As the registry lists them; a condition with its own page is linked.

influenza, sars-cov-2